Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy

Urology

Volumn 49, Issue 3 SUPPL., 1997, Pages 38-45

  Zelefsky, Michael J ^a   Harrison, Amy ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTAMIDE; LEUPRORELIN;

ADJUVANT THERAPY; ADULT; AGED; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; HORMONE INHIBITION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; DRUG THERAPY, COMBINATION; FLUTAMIDE; FOLLOW-UP STUDIES; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 0030950553     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00168-4     Document Type: Conference Paper

References (26)

1. Hanks GE, Martz KL, and Diamond JJ: The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 15: 1299-1305, 1988.
2. Perez CA, Pilipech MV, and Zivnuska F: Tumor control in definitive irradiation of localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 12: 523-531, 1986.
3. Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, Cox JD, Perez CA, Sauge WT, and Doggett SRL, et al: Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 21: 935-936, 1991.
4. Zelefsky MJ, Leibel SA, Burman CA, Kutcher GJ, Harrison A, Happersett L, and Fuks Z: Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 29: 755-761, 1994.
5. Forman JD, Kumar R, Haas G, Montie J, Porter AT, and Mesina CF: Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer Invest 13: 8-15, 1995.
6. Yang FE, Chen GT, Ray P, Vaida F, Chiru P, Hamilton RJ, Spelbring D, Abellera M, and Vijaykumar S: The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. Int J Radiat Oncol Biol Phys 33: 1009-1017, 1995.
7. Leibel SA, Kutcher GJ, Mohan R, Harrison LB, Armstrong JG, Zelefsky MJ, LoSasso TJ, Burman CM, Mageras GS, and Chui CC, et al: Three-dimensional conformal radiation therapy at the Memorial Sloan-Kettering Cancer Center. Semin Radiat Oncol 2: 274-289, 1992.
8. Kaplan EL, and Meier P: Nonparametic estimation from incomplete observations. J Am Stat Assoc 53: 447-457, 1958.
9. Mantel N: Evaluation of survival data and two rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966.
10. Cox DR: Regression models and life tables. J R Stat Soc Series B 34: 187-220, 1972.
11. Smit WGJM, Helle PA, van Putten WLJ, Wijnmaalen AJ, Seldenrath JJ, and van der Werf-Messing BH: Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose, Int J Radiat Oncol Biol Phys 18: 23-29, 1990.
12. Benk VT, Urie MM, Shipley WU, Efird JT, Adams J, Willett CG, McManus PL, and Munzenrider JE: Late rectal bleeding following combined x-ray and proton high dose irradiation for patients with stages T3-T4 prostate carcinoma. Int J Radiat Oncol Biol Phys 26: 551-557, 1993.
13. Leibel SA, Zelefsky MJ, Kutcher GJ, Burman CM, Kelson S, and Fuks Z: Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: interim report of a phase 1 dose escalation study. J Urol 152: 1792-1798, 1994.
14. Zelefsky MJ, Leibel SA, Kutcher GJ, Kelson S, Ling CC, and Fuks Z: The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma. Cancer J Sci Am 1: 142-150, 1995.
15. Hanks GE, Lee WR, Hanlon AL, Kaplan E, Epstein B, and Schultheiss T: Conformal technique dose escalation in prostate cancer: improved cancer control with higher doses in patients with pretreatment PSA > 10 ng/ml. Int J Radiat Oncol Biol Phys 35: 861-868, 1996.
16. Pilepich MV, Sause WT, Shipley WU, Krall JM, Lawton CA, Grignon D, Al-Sarraf M, Abrams RA, Caplan R, and John MJ, et al: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45: 616-623, 1995.
17. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, and Walsh PC: The use of prostate specific antigen, clinical stage and Gleason score to predict pathologic stage in men with localized prostate cancer. J Urol 150: 10-14, 1993.
18. Time Magazine (April 1, 1996)
19. Blasko JC, Wallner K, Grimm PD, and Radgie H: Prostate specific antigen based control following ultrasound guided 125-iodine implantation for stage T1/T2 prostatic carcinoma. J Urol 154: 1096-1099, 1995.
20. Wallner K, Roy J, and Harrison L: Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 14: 449-453, 1996.
21. McCarthy JF, Catalona WJ, and Hudson MA: Effect of radiation therapy on serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment. J Urol 151: 1575-1578, 1994.
22. Critz FA, Tarlton RS, and Holladay DA: Prostate specific antigen monitored combination radiotherapy for patients with prostate cancer. Cancer 75: 2383-2391, 1995.
23. Zeitman AI, Coen JJ, Shipley WI: Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 151: 641-645, 1994.
24. Zelefsky MJ, Leibel SA, Wallner KE, Whitmore WF, and Fuks Z: Significance of normal serum prostate specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer. J Clin Oncol 13: 459-463, 1995.
25. Neerhut GJ, Wheeler T, Cantini M, and Scardino PT: Salvage radical prostatectomy for radiorecurrent adenocarcinoma of the prostate. J Urol 140: 1455-1462, 1988.
26. Link P, and Freiha FS: Radical prostatectomy after definitive radiation therapy for prostate cancer. Urol 37: 189, 1991.